Another study involving camrelizumab plus CRT demonstrated that higher density of PD-L1- macrophages in the baseline tumor compartment was associated with improved PFS (p = 0.032) and in the on-treatment compartment indicated superior OS (p = 0.018) and PFS (p = 0.028) (41, 83). This evidence concerns the gene CD274 and neoplasm.